The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2020

Filed:

Oct. 24, 2018
Applicant:

Abbott Diabetes Care Inc., Alameda, CA (US);

Inventors:

Erwin S. Budiman, Fremont, CA (US);

Gary A. Hayter, Oakland, CA (US);

Nathan Crouther, Camarillo, CA (US);

Marc B. Taub, Mountain View, CA (US);

Wesley Scott Harper, Alameda, CA (US);

Charles Wei, Fremont, CA (US);

Assignee:

Abbott Diabetes Care Inc., Alameda, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61M 31/00 (2006.01); A61M 5/172 (2006.01); A61B 5/145 (2006.01); A61B 5/1495 (2006.01); A61B 5/00 (2006.01); G06F 19/00 (2018.01); G16H 20/17 (2018.01); A61M 5/142 (2006.01);
U.S. Cl.
CPC ...
A61M 5/1723 (2013.01); A61B 5/1495 (2013.01); A61B 5/14532 (2013.01); A61B 5/4839 (2013.01); G06F 19/00 (2013.01); G06F 19/3468 (2013.01); G16H 20/17 (2018.01); A61B 2562/0295 (2013.01); A61M 2005/14208 (2013.01); A61M 2005/14296 (2013.01); A61M 2205/3569 (2013.01); A61M 2205/52 (2013.01); A61M 2230/201 (2013.01);
Abstract

Safety features are applied to an integrated insulin delivery system to enhance safety by controlling medication delivery including the automatic resumption of basal rate after a particular event, such as termination of a bolus, expiration of a time period, delayed resumption after the bolus has terminated, IOB comparison, and others. Other safety features include overriding a delivery control that may result in hypoglycemia, and terminating an extended bolus or temporary basal rate in view of a glucose signal indicating imminent carbohydrate deficiency. In another feature, an automatic resumption of a basal delivery rate is programmed into the delivery device to avoid the possibility of complete loss of delivery of insulin in the event that communication with the delivery device is disrupted.


Find Patent Forward Citations

Loading…